Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in Start Up

Executive Summary

A would-be pulmonary pioneer enters the market via intubation.

You may also be interested in...

Pulmonology: The Next Interventional Cardiology

Pulmonologists, a group of device-friendly physicians without many tools at their disposal, treat large diseases with unmet needs like emphysema, asthma, and lung cancer. They thus represent an attractive, untapped market for medical device companies. Many companies targeting emphysema have been formed by executives from the interventional cardiology industry and aim to follow the tried and true path of that industry, of introducing new minimally-invasive versions of open surgical predicate procedures. Others are following the tougher route of working in diseases like asthma, for which no device predicates exist. Companies hope to offer high volume procedures that will grow interventional pulmonology from a niche specialty treating end-stage cancer patients to a specialty that routinely performs millions of procedures on patients with non-malignant diseases that are currently poorly managed by drugs.

Lungs Expand Device Markets

It's more than a coincidence that cardiology company Boston Scientific has invested in Broncus Technologies and its rival Guidant, in Spiration Inc., two start-ups with minimally-invasive devices for the treatment of lung diseases. Interventional pulmonology could just be the next double-digit growth area to succeed interventional cardiology, which is maturing; what's more, it takes advantage of the core competencies of the big firms.

Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts